Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) Revenue History
Annual and quarterly revenue from 2024 to present
DMAA Revenue Over Time (2024–2025)
DMAA Revenue Growth History
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
DMAA Revenue Analysis (2024–2025)
Current Revenue & Growth
As of June 28, 2026, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
DMAA's historical revenue data shows various trends over time.
Peer Comparison
Compared to Financial Services sector peers — including HCAI, BRTX (-8.5% YoY), and NUVB (+1205.5% YoY). Compare DMAA vs HCAI →
DMAA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| DMAACurrent | $0 | - | - | - | |
 HCAI | $7M | - | - | -322.7% | |
 BRTX | $359,700 | -8.5% | +36.1% | -4350.1% | |
 NUVB | $63M | +1205.5% | - | -338.7% | |
 MRK | $64.9B | +2.5% | +9.4% | 36.2% | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% |
DMAA Historical Revenue Data (2024–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-2,816,013 | - |
| 2024 | $0 | - | $0 | - | $-479 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DMAA — Frequently Asked Questions
Quick answers to the most common questions about buying DMAA stock.
Is DMAA's revenue growth accelerating or slowing?
DMAA TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is DMAA's revenue history from 2024 to 2026?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) revenue history spans 2024 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is DMAA's long-term revenue growth rate (CAGR)?
Drugs Made In America Acquisition Corp. Ordinary Shares's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for DMAA.
Why does DMAA's quarterly revenue fluctuate?
DMAA quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Drugs Made In America Acquisition Corp. Ordinary Shares's revenue data from 2024 to 2026 shows full historical quarterly detail on this page.
How is DMAA's revenue distributed by segment?
DMAA reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does DMAA's revenue compare to industry peers?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.